Investors Step Up for PTC's $30M Round for DMD Trials
Following encouraging results from a Phase III trial, PTC Therapeutics Inc., of South Plainfield, N.J., completed a $30 million financing to support late-stage development of ataluren. The drug has showed clinically meaningful trends in Duchenne's and Becker muscular dystrophy and cystic fibrosis.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST